Tests azithromycin guided by mucus testing or symptoms in adults with COPD
Compares azithromycin given by mucus testing or by symptoms in adults with COPD.
Plain-language title generated from the registry record
Registry title: Chronic Airway Disease, Mucus Rheology and Exacerbations
Key facts
- Where
- Bordeaux, Montpellier, and Toulouse, FranceSee the 3 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT04339270, who can take part
Where in France
- University Hospitals of BordeauxBordeaux, FranceTaking people
- University Hospitals of MontpellierMontpellier, FranceTaking people
- University Hospitals of ToulouseToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT04339270
- Record updated
- 24 September 2026
- Original description
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.Read full original descriptionShow less
Chronic Airway Disease, Mucus Rheology and Exacerbations: a Randomized Controlled Trial of COPD Patients
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
Inclusion: Subjets between 40 - 85 years (included); Written and signed informed consent form; Subjects must be able to attend all planned visits and comply with all test procedures; Beneficiary of or affiliated with the French social security system; Man or woman with chronic obstructive pulmonary disease for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator; Optimal treatment according to GOLD class severity C or D recommendations; >=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months; Spontaneous or induced sputum production; Electrocardiogram: corrected distance between Q and T waves (QTC) <450 ms in men, QTC <470 ms in women; Normal audiogram for age or absence of contraindication to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion.
Exclusion: Received azithromycin in the past 3 months; Concomitant use of medication contraindicated with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine); Known hypersensitivity to azithromycin, erythromycin, any other macrolide, ketolide or any of the excipients of the azithromycin-based specialty used; Other respiratory diseases or associated lung infections; Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion); Patients with hematological malignancies who have undergone allogeneic hematopoietic stem cell transplantation; Renal impairment with creatinine clearance < 40 mL/min; Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax; Pregnancy or breastfeeding; Patients who are prisoners or under other forms of judicial protection; Patients under any form of guardianship; Participation in another interventional protocol, (current or during the month preceding inclusion); Patient whose primary diagnosis is bronchial dilation based on CT scan documentation.